Tiziana Life Sciences announced that it has contracted with CDMO Renaissance Lakewood for development services related to Tiziana’s intranasal foralumab anti-CD3 monoclonal antibody. According to Tiziana, the project includes optimization of the formulation and development of “a comprehensive plan for the scale-up of foralumab in a nasal device.”
Tiziana is developing intranasal foralumab for the treatment of multiple sclerosis and for Alzheimer’s disease. The company also recently received a grant from the ALS association to fund a trial of intranasal foralumab in ALS patients and last year announced results from a preclinical study that demonstrated synergistic effects for intranasal foralumab in combination with semaglutide in a mouse model of obesity.
Renaissance, which specializes in nasal drug delivery, opened its new Lakewood, NJ, USA headquarters in 2024. That site also includes the company’s GMP QC spray lab, which was expanded in 2023, as well as laboratories and manufacturing facilities.
Tiziana Life Sciences CEO Ivor Elrifi commented, “Partnering with Renaissance is a significant milestone in our mission to bring intranasal foralumab to patients in need. Their proven track record in pharmaceutical manufacturing will be invaluable as we advance our clinical programs and prepare for potential market entry.”
Read the Tiziana Life Sciences press release
